(turmeric), and have received much attention due to their pleiotropic anticancer properties. Recent evidence suggests that curcumin and analogs prevent the activation of a variety of signaling pathways, including the MAPK, PI3K/Akt, and NF-kB pathways, resulting in the induction of apoptosis, prevention of proliferation, and suppression. In addition to these processes, curcumin has been shown to enhance the efficacy of the conventional anti-cancer modalities such as radiation and chemotherapy. By suppressing the expression of matrix metalloproteinases (MMPs), which are enzymes that break down the extracellular matrix and promote cancer cell invasion and metastasis, curcumin also demonstrates anti-metastatic qualities. Inflammation and the advancement of cancer are linked to the NF-κB signaling pathways, which are also suppressed by curcuminoids. Along with these processes, curcumin has demonstrated the ability to improve the effectiveness of traditional cancer treatments, including radiation and chemotherapy. It increases the sensitivity of cancer cells to various therapies, which enhances the therapeutic results. However, curcumin's low bioavailability limits its therapeutic use. Its anticancer potency may be increased, and this restriction may be overcome due to recent developments in drug delivery technologies, such as curcumin-loaded nanoparticles. Since they can target several different molecular pathways and improve the effectiveness of current treatments, curcuminoids are a promising family of chemicals for the prevention and treatment of cancer.
The advent of CRISPR‒Cas technology has revolutionized genome editing by providing unprecedented precision, efficiency, and versatility in genetic manipulation. This revolutionary system originated from bacterial adaptive immunity. It allows the programmed modification of DNA sequences in a highly specific way, as long as the desired modification site contains an enzyme-compatible protospacer adjacent motif (PAM) sequence. Recent innovations with CRISPR‒Cas systems have focused on optimizing delivery methods, addressing challenges and expanding their therapeutic applications. Delivery approaches, including viral vectors, lipid nanoparticles, and other nonviral vectors, have been improved to increase target specificity while minimizing off-target effects, ensuring safe and efficient In Vivo genome editing. The applications of CRISPR‒Cas technology include the correction of genetic disorders, engineering of immune cells for cancer therapy, and combating viral infections. However, significant challenges in the form of unintended edits, immune responses, and delivery to specific tissues or organs remain formidable barriers to clinical translation. New CRISPR variants, such as base editing, prime editing, and epigenome editing, provide solutions to improve accuracy and broaden intervention. This review covers recent progress in various CRISPR delivery methodologies, discusses broadening therapeutic applications, highlights ongoing challenges, and describes the future trajectory of this disruptive technology.
Archiv der Pharmazie · مجلد 359 (6) · e70272-e70272
Small-molecule-based therapeutics play a vital role in drug discovery. These molecules are preferred owing to their oral bioavailability, ease of tuning the physicochemical properties, and broad target accessibility. In this review article, we have explored the small molecules approved by the US Food and Drug Administration (USFDA) in 2025. Through the analysis, we found 44 drug approvals, out of which 30 candidates were approved as new molecular entities (NMEs), while the remaining 14 were approved in the category of biologics, including 10 approved as biosimilars. Considering the therapeutic area distribution of 30 NMEs, 28 drugs are approved as monotherapy, with 10 drugs as anticancer agents, 4 drugs for genetic disorders, 2 drugs each for the conditions of immunological, respiratory, ophthalmic, and endocrine disorders, along with the treatment of cardiac and infectious diseases. The structural diversity analysis revealed that 29 approved drugs were aromatic (azaheterocycles) in nature, and 13 drugs possess at least one stereogenic center. Considering the elemental diversity, the near-universal presence of nitrogen in the form of amines, amides, and as a heteroatom, followed by the oxygen atom. Additionally, the prevalence of 3- or 4-membered carbocyclic or heterocyclic rings was found in five approved drugs. For metabolism, most drugs rely on CYP3A-mediated metabolism, primarily through CYP3A4, CYP2D6, and CYP2C8. Collectively, the analysis and compilation of the drugs presented are expected to provide practical insights and offer guidance to medicinal chemists, biologists, and scientists associated with current drug-discovery paradigms, making continuous strides for future medicinal chemistry innovations and evolutions.
FDA-approved drugsnew chemical entitiessmall molecule drugsdrug discovery
Background: Family physicians evaluate skin disorders associated with diagnostic delay, systemic deterioration, tissue destruction, or delayed cancer treatment. These presentations include suspected malignancy, severe drug reactions, and invasive infection, although their referral pathways differ, this review evaluated diagnostic and referral performance in these categories. Methods: Original studies published through 31 Jan 2026 were reviewed using predefined criteria. Patient-based investigations were separated from studies using standardized photographs or clinical vignettes, while cancer pathways were analyzed independently from same-day dermatologic emergencies. Results: Ten studies evaluated diagnostic classification, referral, excision decisions, or image-based recognition. Melanoma sensitivity in general practitioners was 29% in one comparative study, whereas another reported 66.7% sensitivity and 92.0% specificity for recognizing malignant lesions. Following training, dermoscopy increased referral sensitivity from 54.1% to 79.2% without reducing specificity. Sequential dermoscopy reduced excision or referral of suspicious lesions by 56.4%, whereas other diagnostic aids produced inconsistent effects. In an urgent-disease vignette study, family physicians recognized Stevens-Johnson syndrome in 71.4% and pemphigus vulgaris in 28.6% of responses. Conclusion: Diagnostic performance varied according to disease spectrum, clinical setting, physician experience, assessment method, and outcome definition. Training-supported dermoscopy improved selected cancer-triage outcomes, although benefits were not reproduced across all diagnostic technologies.
Cell Biochemistry and Function · مجلد 44 (10) · e70321-e70321
Patient-derived organoids (PDOs) have emerged as an effective experimental platform for bridging the long-standing gap between traditional in vitro cancer models and the biological complexity of actual tumors. These three-dimensional cultures (3D), derived directly from patient tissues, preserve essential architectural, genomic, and phenotypic characteristics of their tumors of origin, enabling more accurate modeling of tumor heterogeneity and disease evolution. Over the last decade, rapid methodological advances in organoid culture systems, extracellular matrices (ECMs), and growth factor optimization have facilitated the establishment of organoid models for a wide range of malignancies and the development of large living biobanks representing diverse patient populations. These models are increasingly being utilized to study cancer biology, elucidate mechanisms of treatment resistance, and evaluate patient-specific therapeutic responses, highlighting their potential as tools for precision oncology. However, important challenges remain, including incomplete representation of the tumor microenvironment (TME), variability in culture conditions, and limited scalability, and the need for greater standardization and validation. Consequently, although PDOs show considerable promise for translational research and personalized medicine, their routine clinical implementation remains largely investigational, and their clinical utility has not yet been fully established. This review examines the technological foundations of PDO generation, assesses their role as experimental models of tumor biology, and discusses their expanding applications in translational cancer research and precision oncology while highlighting key challenges that must be addressed before their widespread clinical adoption.
Oncolytic virotherapy employs genetically modified viruses to selectively lyse tumor cells while activating antitumor immune responses. In pediatric oncology, where outcomes for high-grade gliomas and refractory solid tumors remain poor, oncolytic viruses represent a promising therapeutic strategy. A systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, including searches of PubMed, Embase, Scopus, Web of Science, and ClinicalTrials.gov for studies published between 2015 and 2025 that evaluated oncolytic virotherapy in patients aged 18 years or younger. Data on safety, efficacy, and immune-related outcomes were extracted, study quality was assessed using the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool, and the certainty of evidence was evaluated using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework. Ten early-phase clinical trials involving 115 pediatric patients met the inclusion criteria. Investigated viral platforms included herpes simplex virus type 1 (G207, HSV1716), adenovirus (DNX-2401, ICOVIR-5, Ad-TD-nsIL12), T-VEC (HSV-1), poliovirus (PVSRIPO), Seneca Valley virus, and reovirus. Across studies, no treatment-related deaths or persistent grade 3 or higher toxicities were reported, and adverse events were generally mild and transient. Radiologic or clinical disease control rates ranged from 20% to 90%, with median overall survival between 11 and 18 months in selected central nervous system tumor cohorts. Translational analyses demonstrated increased CD8⁺ T-cell infiltration, upregulation of interferon-γ and interleukin-6 signaling pathways, and evidence of transient viral replication, supporting immune-mediated antitumor mechanisms. Overall risk of bias was moderate, while the certainty of evidence was rated as low for safety outcomes and very low for efficacy. These findings indicate that oncolytic virotherapy is safe, feasible, and biologically active in children with malignant brain and solid tumors, and that preliminary survival signals and consistent immune activation support further investigation through larger, multicenter randomized trials and combination strategies with radiotherapy or immune checkpoint inhibitors.
BACKGROUND: Whole-slide imaging (WSI) has shifted pathology toward digital workflows, creating the foundation for applying artificial intelligence (AI) to diagnostic tasks. This review summarises validated AI applications in diagnostic pathology, with an emphasis on clinical performance, regulatory developments and the practical barriers that affect implementation. METHODS: A structured search of PubMed, Scopus and Google Scholar identified English-language, peer-reviewed studies from January 2020 to May 2025. Eligible studies applied AI to diagnostic, grading or prognostic tasks in human tissue, used a pathologist-confirmed reference standard and included external or multi-centre validation. RESULTS: More than 150,000 digital slides were represented across the included studies. Reported performance metrics demonstrated strong diagnostic accuracy across several validated applications. Large meta-analyses and externally validated studies reported sensitivity values exceeding 96% and specificity above 93% for selected cancer-detection tasks, while other studies demonstrated high agreement for Gleason grading (QWK up to 0.862) and biomarker quantification (Ki-67 ICC 0.98). CONCLUSION: AI has the capacity to strengthen diagnostic pathology by improving consistency, measurement and efficiency. Moving from experimental use to routine reporting will require broad validation across centres, enhanced model transparency, strong quality-assurance systems and close cooperation between developers and pathologists.
Luteolin is widely distributed phytochemical, a flavonoid, in kingdom plantae. Luteolin with potential antioxidant activity prevent ROS-induced damages and reduce oxidative stress which is mainly responsible in pathogenesis of many diseases. Several chemo preventive activities and therapeutic benefits are associated with luteolin. Luteolin prevents cancer via modulation of numerous pathways, that is, by inactivating proteins; such as procaspase-9, CDC2 and cyclin B or upregulation of caspase-9 and caspase-3, cytochrome C, cyclin A, CDK2, and APAF-1, in turn inducing cell cycle arrest as well as apoptosis. It also enhances phosphorylation of p53 and expression level of p53-targeted downstream gene. By Increasing BAX protein expression; decreasing VEGF and Bcl-2 expression it can initiate cell cycle arrest and apoptosis. Luteolin can stimulate mitochondrial-modulated functions to cause cellular death. It can also reduce expression levels of p-Akt, p-EGFR, p-Erk1/2, and p-STAT3. Luteolin plays positive role against cardiovascular disorders by improving cardiac function, decreasing the release of inflammatory cytokines and cardiac enzymes, prevention of cardiac fibrosis and hypertrophy; enhances level of CTGF, TGFβ1, ANP, Nox2, Nox4 gene expressions. Meanwhile suppresses TGFβ1 expression and phosphorylation of JNK. Luteolin helps fight diabetes via inhibition of alpha-glucosidase and ChE activity. It can reduce activity levels of catalase, superoxide dismutase, and GS4. It can improve blood glucose, insulin, HOMA-IR, and HbA1c levels. This review is an attempt to elaborate molecular targets of luteolin and its role in modulating irregularities in cellular pathways to overcome severe outcomes during diseases including cancer, cardiovascular disorders, diabetes, obesity, inflammation, Alzheimer's disease, Parkinson's disease, hepatic disorders, renal disorders, brain injury, and asthma. As luteolin has enormous therapeutic benefits, it could be a potential candidate in future drug development strategies.
ABSTRACT Anthocyanins (Anthos; flower and kyanos; blue) are natural coloring compounds from the flavonoids class that include cyanidin, peonidin, delphinidin, malvidin, pelargonidin, and petunidin. Recently, the role of anthocyanins in disease prevention, especially inflammation, diabetes, cancer, neuro‐disorders, hepato‐renal protective, and immuno‐modulation properties has been highlighted. The current review covered the literature on the pharmacokinetics and pharmacological effects of anthocyanins, especially absorption, distribution, metabolism, and excretion (ADME). The discussion on molecular mechanisms underlying their therapeutic effects is the limelight of the article. The GLUT1, GLUT3, SGLT1, SMCT1, and SMCT2 are the main carriers involved in the transportation of anthocyanins in the gastrointestinal tract. The anthocyanins exert their anticancer effects by reducing the expression of IL‐6, IL‐1β, TNF‐β, COX‐2, downregulation of NF‐kB, EZH2, MDR1, Akt , and modulation of P13K/AKT and AMPK/mTOR pathways. The reduction in α‐amylase and α‐glucosidase and improved FFAR1 activity results in antidiabetic effects. The regulation of PGC‐1α/NRF2/TFAM, p‐PI3K/Akt/GSK3β, and Nrf2/HO‐1 prevents neurodegeneration. The anthocyanins impose hepato‐renal protective effects via ameliorating NLRP3 inflammasome, inhibiting MDA, GSSG, iNOS, HO‐1, ICAM‐1, β2‐microglobulin, and MPO activity, and improved SOD, CAT, and GSH activity. Anthocyanins promote beneficial gut microbiota and enhance SCFA production, thus inhibiting pro‐inflammatory markers. The immuno‐modulatory impact of anthocyanins involves the reduction of CRP, P‐selectin, C1q, and C4. Anthocyanins reduce LDL, VLDL, TGs, and TC via improved GBA and upregulation of ATP6 V0C, ZO‐1, and ATG4D expression. The WHO/FAO suggested that 2.5 mg/kg/day of grape‐skin extracts of anthocyanins are safe, and China recommended that 50 mg/day of anthocyanins are safe for consumption. In a nutshell, the multifaceted health benefits of anthocyanins make them promising candidates for disease prevention and therapeutic interventions.